報價延遲最少15分鐘:2024/09/21 01:15 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
60 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.76/1.79
|
|
企業價值
15.76B
|
| 資產負債 |
|
每股賬面淨值
19.86
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
4.38B
|
|
每股收益
24.91
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/09/21 01:15 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenuesprimarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |